Welcome to our dedicated page for RECURSION PHARMACEUTICALS SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
RECURSION PHARMACEUTICALS, INC. (RXRX) is the issuer for which officer Najat Khan has filed a Rule 144 notice to potentially sell shares of common stock. The notice covers 22,408 shares, with an indicated aggregate market value of $78,822.38, to be sold through Merrill Lynch on NASDAQ.
The shares include blocks of 18,422 and 6,477 common shares that were acquired as equity compensation on August 15, 2026. The filing does not itself report that any sale has occurred; it gives advance notice of a possible sale under Rule 144.
RECURSION PHARMACEUTICALS, INC. (RXRX) director Blake Borgeson sold shares of the company’s Class A Common Stock. On September 1, 2026, he sold 30,000 shares at an average price of $3.34 per share in an open-market or private transaction. Following this sale, he continued to hold 6,158,287 shares of Class A Common Stock directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025, indicating the transaction was pre-arranged under that plan.
RECURSION PHARMACEUTICALS, INC. (RXRX) director Blake Borgeson has filed a Form 144 indicating an intent to sell 30,000 Class A shares of Recursion through Fidelity Brokerage Services LLC, with an approximate aggregate value of $100,200. The shares were originally acquired on 09/19/2017 as Founders Shares received as compensation. The notice also lists prior Rule 144 sales over the last three months.
RECURSION PHARMACEUTICALS, INC. (RXRX) is the issuer of Class A common stock covered by this Rule 144 notice. Former director Christopher C. Gibson has filed to sell 77,290 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $262,013.10, listed on NASDAQ. The notice also lists multiple Class A share sales over the prior three months by Gibson, the Gibson Family Trust, and Lahwran-3 LLC, for which Gibson is an authorized individual or trustee.
RECURSION PHARMACEUTICALS, INC. (RXRX) received a Rule 144 notice covering planned sales of 75,000 Class A shares held for the account of former director Christopher C. Gibson. The shares are held at Fidelity Brokerage Services LLC, with an aggregate market value of $255,000.00 and are listed on NASDAQ. The notice also details extensive Class A share sales during the prior three months by Gibson, Lahwran-3 LLC, and the Gibson Family Trust, entities for which Gibson is an authorized individual, trustee, or account stakeholder.
RECURSION PHARMACEUTICALS, INC. (RXRX) has a planned secondary sale of Class A common stock by former director Christopher C. Gibson under Rule 144. The notice covers up to 100,000 Class A shares, with an indicated aggregate market value of 327,500.00, to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The disclosure also lists multiple prior Class A share sales in the past three months by Gibson, Lahwran-3 LLC, and the Gibson Family Trust, with Gibson identified as an authorized individual or trustee for those accounts.
RECURSION PHARMACEUTICALS, INC. (RXRX) reported that CEO and President Najat Khan had 80,498 shares of Class A Common Stock withheld on 2026-08-17. These shares were withheld by the company to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units, not sold in an open-market transaction. After this withholding, Khan directly holds 2,095,298 shares of Class A Common Stock.
RECURSION PHARMACEUTICALS, INC. (RXRX) reported that Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on 2026-08-17 to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units. This reduced his position for tax purposes only; his direct holdings after this event are 1,043,837 shares of Class A common stock.
RECURSION PHARMACEUTICALS, INC. (RXRX) reported that its Chief Financial Officer, Ben R. Taylor, had 25,018 shares of Class A Common Stock withheld on 2026-08-17 to satisfy tax withholding and remittance obligations in connection with the net settlement of restricted stock units. This tax-withholding disposition was recorded at $3.16 per share, and Taylor now directly holds 1,076,858 shares of Class A Common Stock.
RECURSION PHARMACEUTICALS, INC. (RXRX) is the issuer of Class A common stock for which Christopher C. Gibson, a former director, has filed a Rule 144 notice. The filing covers the proposed sale of 26,806 Class A shares, originating from restricted stock vesting on 08/17/2026, with part of the sale intended to cover a tax obligation from a vested equity award distribution. The notice also lists extensive Class A share sales during the prior three months by Gibson, Lahwran-3 LLC, and the Gibson Family Trust.